Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume – Should You Buy?

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) saw an uptick in trading volume on Tuesday . 17,811 shares changed hands during trading, an increase of 81% from the previous session’s volume of 9,821 shares.The stock last traded at $16.9190 and had previously closed at $16.28.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Zacks Research upgraded Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a research report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $38.00.

Pharming Group Stock Performance

The company has a market cap of $1.14 billion and a PE ratio of -1,658.84. The company has a current ratio of 3.16, a quick ratio of 2.39 and a debt-to-equity ratio of 0.35. The business’s 50 day moving average is $15.45 and its two-hundred day moving average is $13.39.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.05. Pharming Group had a return on equity of 0.46% and a net margin of 0.30%.The business had revenue of $97.30 million during the quarter, compared to analyst estimates of $98.22 million. On average, equities research analysts anticipate that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 52,147 shares of the company’s stock after purchasing an additional 4,150 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.